4/27
08:01 am
iova
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
Low
Report
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
4/22
10:31 am
iova
Iovance Biotherapeutics Inc (IOVA): Jefferies Draws Attention Amtagvi Drug [Yahoo! Finance]
Low
Report
Iovance Biotherapeutics Inc (IOVA): Jefferies Draws Attention Amtagvi Drug [Yahoo! Finance]
4/17
05:15 pm
iova
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
4/17
04:13 pm
iova
Is Iovance Biotherapeutics (IOVA) Pricing In Its Rebound After Strong Year To Date Gains? [Yahoo! Finance]
Low
Report
Is Iovance Biotherapeutics (IOVA) Pricing In Its Rebound After Strong Year To Date Gains? [Yahoo! Finance]
4/10
03:42 pm
iova
Iovance Biotherapeutics (IOVA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $16.00 price target on the stock.
Low
Report
Iovance Biotherapeutics (IOVA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $16.00 price target on the stock.
4/8
06:04 am
iova
Iovance Biotherapeutics (IOVA) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
Low
Report
Iovance Biotherapeutics (IOVA) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
4/6
10:11 pm
iova
Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback [Seeking Alpha]
Low
Report
Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback [Seeking Alpha]
3/31
04:48 am
iova
Iovance Biotherapeutics: Competition Afoot, But New Indications Can Help [Seeking Alpha]
Medium
Report
Iovance Biotherapeutics: Competition Afoot, But New Indications Can Help [Seeking Alpha]
3/26
05:49 am
iova
Iovance Biotherapeutics (IOVA) was upgraded by Truist Financial Corporation to "hold".
Low
Report
Iovance Biotherapeutics (IOVA) was upgraded by Truist Financial Corporation to "hold".
3/23
09:58 am
iova
Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors [Yahoo! Finance]
Medium
Report
Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors [Yahoo! Finance]
3/20
05:15 pm
iova
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
3/13
11:11 pm
iova
Iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas [Yahoo! Finance]
Low
Report
Iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas [Yahoo! Finance]
3/8
10:34 pm
iova
Iovance Sarcoma Trial Data Puts TIL Platform And Stock In Focus [Yahoo! Finance]
Medium
Report
Iovance Sarcoma Trial Data Puts TIL Platform And Stock In Focus [Yahoo! Finance]
3/7
08:17 pm
iova
Iovance (IOVA) Soars 33%, Hits All-Time High [Yahoo! Finance]
Medium
Report
Iovance (IOVA) Soars 33%, Hits All-Time High [Yahoo! Finance]
3/7
01:38 am
iova
Iovance (IOVA) Hits 52-Week High as Analyst Doubles Price Target [Yahoo! Finance]
Medium
Report
Iovance (IOVA) Hits 52-Week High as Analyst Doubles Price Target [Yahoo! Finance]
3/6
12:18 pm
iova
UBS Raises PT on Iovance Biotherapeutics (IOVA) [Yahoo! Finance]
Low
Report
UBS Raises PT on Iovance Biotherapeutics (IOVA) [Yahoo! Finance]
3/5
05:55 pm
iova
Iovance Biotherapeutics: The High-Risk Cancer Stock I Think Could Change a Portfolio by 2036 [Yahoo! Finance]
High
Report
Iovance Biotherapeutics: The High-Risk Cancer Stock I Think Could Change a Portfolio by 2036 [Yahoo! Finance]
3/5
10:24 am
iova
Iovance Biotherapeutics (IOVA) had its price target raised by UBS Group AG from $2.00 to $4.00. They now have a "neutral" rating on the stock.
High
Report
Iovance Biotherapeutics (IOVA) had its price target raised by UBS Group AG from $2.00 to $4.00. They now have a "neutral" rating on the stock.
3/3
08:50 am
iova
Iovance Biotherapeutics (IOVA) was upgraded by Citizens Jmp from "market perform" to "market outperform". They now have a $5.00 price target on the stock.
Low
Report
Iovance Biotherapeutics (IOVA) was upgraded by Citizens Jmp from "market perform" to "market outperform". They now have a $5.00 price target on the stock.
2/27
07:35 pm
iova
Iovance Biotherapeutics (IOVA) Reports 61% Annual Revenue Growth Driven by Amtagvi Success [Yahoo! Finance]
Low
Report
Iovance Biotherapeutics (IOVA) Reports 61% Annual Revenue Growth Driven by Amtagvi Success [Yahoo! Finance]
2/27
04:21 pm
iova
Is Iovance Biotherapeutics (IOVA) Pricing Reflect Recent Cell Therapy Progress Accurately [Yahoo! Finance]
Low
Report
Is Iovance Biotherapeutics (IOVA) Pricing Reflect Recent Cell Therapy Progress Accurately [Yahoo! Finance]
2/26
08:00 am
iova
Iovance Biotherapeutics to Present at Upcoming Conferences
Low
Report
Iovance Biotherapeutics to Present at Upcoming Conferences
2/25
10:58 am
iova
Iovance Biotherapeutics (IOVA) had its price target raised by Barclays PLC from $10.00 to $11.00. They now have an "overweight" rating on the stock.
High
Report
Iovance Biotherapeutics (IOVA) had its price target raised by Barclays PLC from $10.00 to $11.00. They now have an "overweight" rating on the stock.
2/25
09:24 am
iova
Iovance Biotherapeutics (IOVA) had its price target lowered by Chardan Capital from $17.00 to $16.00. They now have a "buy" rating on the stock.
Medium
Report
Iovance Biotherapeutics (IOVA) had its price target lowered by Chardan Capital from $17.00 to $16.00. They now have a "buy" rating on the stock.
2/25
08:12 am
iova
Iovance Biotherapeutics Inc (IOVA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Medium
Report
Iovance Biotherapeutics Inc (IOVA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]